Log in to save to my catalogue

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluatio...

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluatio...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_21ea7ba220ad4b319c9536d754e3134f

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

About this item

Full title

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

Publisher

London, England: SAGE Publications

Journal title

Therapeutic advances in medical oncology, 2024-01, Vol.16, p.17588359231217958

Language

English

Formats

Publication information

Publisher

London, England: SAGE Publications

More information

Scope and Contents

Contents

Background:
Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) develop visceral metastases, which are associated with a poor prognosis.
Objectives:
Efficacy of enzalutamide in mCRPC patients with measurable metastases, including visceral and/or extra-regional lymph nodes.
Methods:
In this phase II mult...

Alternative Titles

Full title

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_21ea7ba220ad4b319c9536d754e3134f

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_21ea7ba220ad4b319c9536d754e3134f

Other Identifiers

ISSN

1758-8359,1758-8340

E-ISSN

1758-8359

DOI

10.1177/17588359231217958

How to access this item